Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis

Foster CS (2003) Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol 14(6):395–398

Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34(5):1146–1150

Kay J, Rahman MU (2010) Golimumab: a novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 4:159–170

Jabs DA, Nussenblatt RB, Rosenbaum JT, G. Standardization of Uveitis Nomenclature Working (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516

Cordero-Coma M, Salom D, Diaz-Llopis M, Lopez-Prats MJ, Calleja S (1892) (2011) Golimumab for uveitis. Ophthalmology 118(9):e3–e4

Schoels M, Aletaha D, Smolen JS, Wong JB (2012) Comparative effectiveness and safety of biological treatment options after tumour necrosis factor alpha inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis

Ash Z, Emery P (2011) Golimumab—a new tool in the armoury against inflammatory arthritis. Ann Med 43(2):133–141